Viewing a single comment thread. View all comments

Cheddarific OP t1_is4buvh wrote

Reply to comment by bio_med_guy in Why do solid tumor oncology clinical trials commonly use transcriptomics instead of measuring specific protein biomarkers? by Cheddarific

Transcriptome is undoubtedly fascinating in oncology, but the real question is how that translates into actual proteins, right? Like measuring the amount of time each student studies each textbook page for a test rather than capturing the actual results of the test; you get more data one way, but the data you really want is the smaller set, right?

1

bio_med_guy t1_is4tp5k wrote

Yeah okay, didn't understand your question. The problem with proteomics is you need alot of starting material in order to get data, specially when talking about discovery highthrouput data which sometimes is not available in case of patients in clinial trials. In cases of clinical practice you do not need that much, as different techniques are being used such as flow cytometry, which works for few biomarkers but not for highthrouput discovery data. However that limitation is being approached now from several directions including spatial proteomics.

On the other hand, transcriptomic analysis can be done with very small amount of starting material, and with much cheaper price. Simply as this amount will be amplified during the procedure, which cannot be achieved for proteomics.

Did that answer your question??

2